Differential responses to 223Ra and Alpha-particles exposure in prostate cancer driven by mitotic catastrophe

IntroductionRadium-223 (223Ra) has been shown to have an overall survival benefit in metastatic castration-resistant prostate cancer (mCRPC) involving bone. Despite its increased clinical usage, relatively little is known regarding the mechanism of action of 223Ra at the cellular level.MethodsWe eva...

Full description

Bibliographic Details
Main Authors: Francisco D. C. Guerra Liberal, Hugo Moreira, Kelly M. Redmond, Joe M. O’Sullivan, Ali H. D. Alshehri, Timothy C. Wright, Victoria L. Dunne, Caoimhghin Campfield, Sandra Biggart, Stephen J. McMahon, Kevin M. Prise
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-07-01
Series:Frontiers in Oncology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.877302/full